UPDATE 2-GSK flags up pipeline as HIV drugs help it beat profit forecasts
* HIV sales help offset margin slide post Novartis deal * Q2 core EPS 17.3 pence vs consensus 16.7p * Q2 sales 5.9 billion pounds, in line with consensus * GSK says has around 40 new drugs and vaccines in Phase II/III * Shares up more than 3 percent on earnings beat (Add
Read more